AIMMAX THERAPEUTICS INC

Durham, NC · Founded 2016 · CIK 0001701803 · Biotech · Private

AMX-2005, a novel broad-spectrum antibiotic molecule with activity against MRSA and VRE

aimmaxrx.com →
Grants
$6.8M
12 awards
Sector median: 1
Raised
$200K
1 Form D · Apr 2017
114 months since last filing
Contracts
—
No federal contracts on record
Patents
9
0 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$200,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides$612,894
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides$306,486
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea$306,915
Federal grantDepartment of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides$306,408
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections$306,954
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections$306,954
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea$999,962
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea$999,962
Federal grantDepartment of Health and Human Services · Phase II · A Single Dose Therapy to Treat Drug Resistant Gonorrhea$306,497
Federal grantDepartment of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections$306,953
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea$999,991
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea$1,049,943
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1196VICOLINE MEDICAL, LLC——
1197Khartis Therapeutics——
1198TATEVA THERAPEUTICS INC.——
1199AIMMAX THERAPEUTICS INC—$200K
1200DMC BIOTECHNOLOGIES, INC.—$47M
1201Obatala Sciences, Inc.—$200K
1202Oncorus, Inc.—$47M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Laurene WangDirector · Executive Officer

Patents

USPTO · 0 granted of 9
  • Pristinamycin Ia And Flopristin Combinations In Treating Or Preventing Bacterial Infectionsapplication
  • Peptides With Antimicrobial Activitiesapplication
  • Streptogramin A Monotherapy For Treating Or Preventing Bacterial Infectionsapplication
  • Corticosteroid Nanosuspensions And Uses For Treating Burn Injuries, Allergic Rhinitis, Meniere's Disease, Tenosynovitis And Arthritisapplication
  • Use Of A Streptogramin A Monotherapy In Treating Or Preventing Bacterial Infectionsapplication
  • Peptides With Antimicrobial Activitiesapplication
  • Corticosteroid Nanosuspensions And Uses Thereofapplication
  • Pristinamycin Ia And Flopristin Combinations In Treating Or Preventing Bacterial Infectionsapplication
  • Corticosteroid Nanosuspensions And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.